Linagliptin: Cardiovascular and Renal Safety beyond Doubt at a Steep Price
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pharmacology and Pharmacotherapeutics"
DOI: 10.4103/jpp.jpp_10_20
Abstract: Dipeptidyl peptidase-IV inhibitors or “gliptins” are commonly used oral anti-diabetic drugs for Type 2 diabetes mellitus, preferred as add-on therapy after metformin. Various cardiovascular outcome trials (CVOTs) have established their cardiovascular safety. Approved later than… read more here.
Keywords: safety beyond; price; renal safety; linagliptin cardiovascular ... See more keywords